Ohio State’s Drug Development Institute (DDI) 
Pharmaceutical Industry Lecture Series

“Antibody Drug Conjugates: From Early-Stage Research to a Clinically Approved Drug”

Monday, May 14  
12:30-1:30 p.m.  
Lunch will be provided.

Biomedical Research Tower, Room 115  
460 W. 12th Avenue  
Columbus, OH 43210

Featuring:

**Peter Senter, PhD**  
Vice President, Chemistry  
Distinguished Research Fellow  
Seattle Genetics, Inc.  
Bothell, Wash.

To RSVP, contact:  
ddi@osumc.edu

Antibody-drug conjugates (ADC) are an integral part of the evolving cancer treatment paradigm. Learn how Seattle Genetics’ ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and the power of potent cell-killing agents to treat cancer. Seattle Genetics is a global oncology biotechnology company focused on developing and commercializing a new generation of targeted antibody-based therapies for cancer patients.

For more information about the OSUCCC – James Drug Development Institute, visit [go.osu.edu/DDI](http://go.osu.edu/DDI).

The James